Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Four year follow up analysis data for Taxus DES trial is released

Boston Scientific : 23 May, 2007  (New Product)
Boston Scientific has announced the four year follow-up data from the Taxus VI clinical trial.
The data demonstrated that the safety and efficacy benefits associated with a moderate release formulation of the Taxus Express paclitaxel-eluting Stent system - which is not approved for commercial distribution - were maintained at four years with no new Stent thrombosis reported after two years.

Analysis of the data was presented by Professor Eberhard Grube, MD, Heart Center Siegburg, Germany, the co-principal investigator of the trial.

'Even though the moderate release Taxus formulation, with an 8 to 10 fold higher in vitro dose, was never commercialised, the excellent ongoing results in Taxus VI further demonstrate the margin of safety of the commercial slow-release Taxus Stent now implanted in more than four million patients worldwide', said Paul LaViolette, Boston Scientific chief operating officer.

'With no Stent thrombosis after two years, a low cardiac death rate, and a low TLR rate, we continue to be impressed with how paclitaxel performs in this high-risk patient population'.

'The four year results from Taxus VI demonstrate that the safety and efficacy benefits associated with the moderate release Taxus paclitaxel-eluting Stent system were maintained in patients with complex coronary artery disease at four years', said Professor Grube.

'The performance of the Taxus Stent in these patients was extremely impressive when considering the complexity of their disease, including patients with long lesions, small vessels, and those requiring multiple, overlapping stents'.

The randomised, double-blind, controlled study of 446 patients at 44 international sites is designed to assess the Taxus moderate release paclitaxel-eluting coronary Stent system in reducing restenosis in high-risk patients, including de novo lesions with overlapping stents, lesions 26mm or greater in length and small vessels.

Lesion size ranged from 18 to 40mm in length and 2.5 to 3.75mm in diameter.

Taxus VI is the first randomised, controlled clinical trial to demonstrate durability of drug-eluting stents in complex lesions at four years.

Follow-up included 98 percent of the patients enrolled at four years.

The study's results demonstrate a continued significant reduction in target lesion revascularisation (TLR, or retreatment rate) as compared to the bare-metal Stent control group at four years.

The four year TLR rate was 12.9 percent for the Taxus Stent group, as compared with 21.4 percent for the control group (P=0.0082 (only two TLR events were reported between three and four years for the Taxus Stent group)).

The rate of patients living free of TLR events was 87.1 percent at four years for the Taxus Stent group, as compared to 78.6 percent for the bare-metal Stent control group.

The four year results for Taxus VI support long term safety with the increased levels of paclitaxel in the moderate-release formulation used in the study.

Even with an in vitro dosing rate 8 to 10 times greater than the commercialised slow-release formulation, no compromise in safety was observed.

The Taxus Stent group continues to report no new Stent thrombosis after two years with a low 2.4 percent cardiac death rate.

Boston Scientific launched the slow-release formulation Taxus Express2 paclitaxel-eluting coronary Stent system in Europe and other international markets in 2003 and in the United States in 2004.

The company launched the slow-release formulation Taxus Liberte paclitaxel-eluting coronary Stent system in Europe and other international markets in 2005.

The Taxus Express moderate-release paclitaxel-eluting Stent is not approved for commercial distribution.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo